Advanced search
Publication Cover
Journal of Medical Economics Volume 22, 2019 - Issue 12
Submit an article Journal homepage
2,877
Views
12
CrossRef citations to date
0
Altmetric
Hematology

Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events

Anisha M. PatelGenentech, Inc, San Francisco, CA, USA; Correspondence[email protected]
,
Shelby L. CormanPharmerit International, Bethesda, MD, USA;
,
Stephen ChaplinPharmerit International, Bethesda, MD, USA;
,
Karina RaimundoGenentech, Inc, San Francisco, CA, USA;
&
Robert F. SidonioAflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, USA
Pages 1328-1337 | Received 30 Jul 2019, Accepted 06 Sep 2019, Published online: 07 Oct 2019

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Maria Elisa Mancuso, Giancarlo Castaman, Michal Pochopien, Samuel Aballéa, Aleksandra Drzewiecka, Zalmai Hakimi, Jameel Nazir & Francis Fatoye. (2022) Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe. Journal of Medical Economics 25:1, pages 1068-1075.
Read now
E. Carlos Rodriguez-Merchan. (2020) The cost of hemophilia treatment: the importance of minimizing it without detriment to its quality. Expert Review of Hematology 13:3, pages 269-274.
Read now

Articles from other publishers (10)

Carmen Escuriola Ettingshausen, Renchi Yang, Wenman Wu & Shannon L. Meeks. (2022) Inhibitors: Diagnostic challenges, unknowns of inhibitor development, treatment of bleeding and surgery, and insights into diagnosis and treatment in China. Haemophilia 28:S4, pages 111-118.
Crossref
Johnny Mahlangu, Alfonso Iorio & Gili Kenet. (2022) Emicizumab state‐of‐the‐art update. Haemophilia 28:S4, pages 103-110.
Crossref
Guy Young. (2021) Management of children with hemophilia A: How emicizumab has changed the landscape. Journal of Thrombosis and Haemostasis 19:7, pages 1629-1637.
Crossref
Ladislas Capdevila, Delphine Borgel, Dominique Lasne, Sebastien Lacroix‐Desmazes, Maximilien Desvages, Sandrine Delignat, Cécile Bally, Laurent Frenzel & Annie Harroche. (2021) Reappearance of inhibitor in a tolerized patient with severe haemophilia A during FVIII‐free emicizumab therapy. Haemophilia 27:4.
Crossref
Cihan Ay, Clemens Feistritzer, Joachim Rettl, Gerhard Schuster, Anna Vavrovsky, Leonard Perschy & Ingrid Pabinger. (2021) Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria. Scientific Reports 11:1.
Crossref
Santiago Bonanad, María Teresa Álvarez, Ramiro Núñez, José Luis Poveda, Beatriz Gil, Elena Ruíz-Beato, Ana Durán, Yoana Ivanova, Inés Pérez-Román & Almudena González-Domínguez. (2021) Costs of the management of hemophilia A with inhibitors in Spain. Global & Regional Health Technology Assessment 8, pages 35-42.
Crossref
Midori Shima & Robert F. SidonioJrJr. (2020) Substitution therapy. Haemophilia 27:S3, pages 53-59.
Crossref
Anisha M. Patel, Wendy E. Owens, Kathleen Poulos, Karina Raimundo, Gabriel Wong, Janet Bernard, Janet Powers & Richard H. Ko. (2021) Haemophilia A management with emicizumab: A survey of haematologists in the United States. The Journal of Haemophilia Practice 8:1, pages 155-182.
Crossref
Hankil Lee, Hyeonseok Cho, Jung Woo Han, Ah‐Young Kim, Seonyoung Park, Minjun Lee, Sunghwa Cho, Deborah Baik & Hye‐Young Kang. (2020) Cost‐utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea. Haemophilia 27:1.
Crossref
Laurie J. Brown, Hai A. La, Jinjing Li, Matthias Brunner, Martin Snoke & Annette M. Kerr. (2020) The societal burden of haemophilia A. III – The potential impact of emicizumab on costs of haemophilia A in Australia. Haemophilia 26:S5, pages 21-29.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.